American firm Agilent Technologies Inc. has announced an agreement with US-based Incyte, an American multinational pharmaceutical company with headquarters in Delaware, and Switzerland, that will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialisation of Incyte’s hematology and oncology portfolio.

The value of the companion diagnostics market is predicted to expand to nearly $14 billion by 2030, driven in part by the power of these tests to inform treatment decisions for a growing range of cancers and other chronic diseases. Developed for use with targeted therapeutics, companion diagnostics are used to evaluate expression of biomarkers and identify patients that are likely to benefit from treatment with the targeted therapeutic products.

The agreement between Agilent and Incyte allows the companies to collaborate on CDx development programmes. This will enable Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers and Incyte to leverage Agilent’s expertise in IVD assay development, global regulatory approvals, and commercialisation to support clinical trials as well as the potential registration and commercialisation of CDx in the United States and Europe.